负荷量瑞舒伐他汀对急性ST段抬高型心肌梗死急诊介入治疗患者的影响

被引:24
作者
李平
黄翠娟
甘剑挺
梁祥文
陈坚
王正东
机构
[1] 广西医科大学第六附属医院心内科
关键词
他汀类; 急性心肌梗死; 经皮冠状动脉成形术;
D O I
10.13699/j.cnki.1001-6821.2013.10.007
中图分类号
R542.22 [];
学科分类号
1002 ; 100201 ;
摘要
目的探讨负荷量瑞舒伐他汀对急性ST段抬高型心肌梗死(STEMI)行急诊介入治疗(PCI)的临床效果。方法选取2010年4月1日至2013年4月1日入院的STEMI并行急诊PCI治疗的患者共203例,随机分为负荷剂量组(103例)和常规剂量组(100例),负荷量组PCI治疗前口服瑞舒伐他汀钙20 mg,常规量组行PCI治疗前口服瑞舒伐他汀钙10 mg;2组术后均继续每天口服瑞舒伐他汀钙10 mg。比较2组术后心肌血流灌注、相关生化指标的变化以及患者术后1个月主要不良心血管事件(MACE)的发生。结果心肌血流灌注负荷量组优于常规量组;2组介入手术24 h后超敏C反应蛋白(hsCRP)、肌酸激酶MB(CKMB)、白介素6(IL-6)、基质金属蛋白酶9(MMP-9)和炎症因子高迁移率族蛋白1(HMGB-1)等生化指标均有所升高,但负荷量组各生化指标升高幅度均小于常规量组(P<0.05)。2组患者围手术期MACE的发生率比较差别无统计学意义。术后1个月随访显示所有患者未发生药物不良反应。结论短期观察,负荷量瑞舒伐他汀与常规量比较,未能减少STEMI患者行PCI围手术期主要不良心血管事件的发生,但有更好的抗炎作用及改善介入治疗术后心肌血流灌注。
引用
收藏
页码:732 / 735
页数:4
相关论文
共 7 条
[1]   Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary Angioplasty [J].
Oduncu, Vecih ;
Tanalp, Ali Ceyat ;
Erkol, Ayhan ;
Sirma, Dicle ;
Dundar, Cihan ;
Akgun, Taylan ;
Turkyilmaz, Erdem ;
Kilicgedik, Alev ;
Gozubuyuk, Gokhan ;
Tigen, Kursat ;
Izgi, Akin ;
Kirma, Cevat .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (02) :179-185
[2]  
Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction[J] . Jung-Sun Kim,Jaedeok Kim,Donghoon Choi,Chan Joo Lee,Sang Hak Lee,Young-Guk Ko,Myeong-Ki Hong,Byoung-Keuk Kim,Seong Jin Oh,Dong Woon Jeon,Joo-Young Yang,Jung Rae Cho,Nam-Ho Lee,Yun-Hyeong Cho,Deok-Kyu Cho,Yangsoo Jang.JACC: Cardiovascular Interventions . 2010 (3)
[3]  
The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J] . Kyeong Ho Yun,Myung Ho Jeong,Seok Kyu Oh,Sang Jae Rhee,Eun Mi Park,Eun Mi Lee,Nam Jin Yoo,Nam-Ho Kim,Young Keun Ahn,Jin-Won Jeong.International Journal of Cardiology . 2008 (3)
[4]  
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention[J] . Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Marco Miglionico,Dionigi Fischetti,Gennaro Sardella,Antonio Montinaro,Germano Di Sciascio.Journal of the American College of Cardiology . 2007 (12)
[5]  
Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: A retrospective study in patients undergoing primary percutaneous coronary intervention[J] . Hideki Ishii,Satoshi Ichimiya,Masaaki Kanashiro,Toru Aoyama,Yasuhiro Ogawa,Ryuichiro Murakami,Tetsuya Amano,Keiko Naruse,Tatsuaki Matsubara,Toyoaki Murohara.Clinical Therapeutics . 2006 (11)
[6]   Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome [J].
Chang, SM ;
Yazbek, N ;
Lakkis, NM .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 62 (02) :193-197
[7]   No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention [J].
Resnic, FS ;
Wainstein, M ;
Lee, MKY ;
Behrendt, D ;
Wainstein, RV ;
Ohno-Machado, L ;
Kirshenbaum, JM ;
Rogers, CDK ;
Popma, JJ ;
Piana, R .
AMERICAN HEART JOURNAL, 2003, 145 (01) :42-46